O'Shaughnessy Asset Management’s NovoCure NVCR Stock Holding History

O'Shaughnessy Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,392	Closed	-$162K	–	2056
2021 Q3	$162K	Sell	1,392 -3,832	-73%	-$579K	﹤0.01%	1130
2021 Q2	$1.16M	Buy	5,224 +441	+9%	+$85.8K	0.02%	439
2021 Q1	$632K	Buy	4,783 +3,461	+262%	+$547K	0.01%	520
2020 Q4	$229K	Buy	1,322 +1,269	+2,394%	+$174K	0.01%	783
2020 Q3	$6K	Sell	53 -1,141	-96%	-$91.2K	﹤0.01%	1461
2020 Q2	$71K	Hold	1,194	–	–	﹤0.01%	927
2020 Q1	$81K	Hold	1,194	–	–	﹤0.01%	673
2019 Q4	$100K	Buy	+1,194	New	+$96.4K	﹤0.01%	795

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

O'Shaughnessy Asset Management's NVCR Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 1,392 shares — an estimated $162K sold.

O'Shaughnessy Asset Management first reported a position in NVCR in Q4 2019 and held it in 8 quarters. The position peaked at $1.16M in Q2 2021. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

O'Shaughnessy Asset Management reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
O'Shaughnessy Asset Management sold 1,392 NovoCure shares in Q4 2021, an estimated $162K.
O'Shaughnessy Asset Management first reported a position in NovoCure in Q4 2019 and held it in 8 quarters.
O'Shaughnessy Asset Management's NovoCure position peaked at $1.16M in Q2 2021.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.